Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single Arm Multiple Dose Study to Assess the Efficacy and Safety of ANB019 in Subjects With Generalized Pustular Psoriasis

Trial Profile

A Single Arm Multiple Dose Study to Assess the Efficacy and Safety of ANB019 in Subjects With Generalized Pustular Psoriasis

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 May 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Imsidolimab (Primary) ; Imsidolimab (Primary)
  • Indications Generalised pustular psoriasis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms GALLOP
  • Sponsors AnaptysBio
  • Most Recent Events

    • 06 May 2020 According to an AnaptysBio media release, Enrollment of the GALLOP and POPLAR trials has been enhanced by expanding clinical sites and geographies involved. While the Company does not believe that the aforementioned timelines are materially impacted by the COVID-19 pandemic at this point, some of the sites involved in the GALLOP and POPLAR trials have been affected by the COVID-19 pandemic, and the Company will continue to monitor the situation over the upcoming months.
    • 06 May 2020 According to an AnaptysBio media release, Company anticipates additional clinical data and a regulatory strategy update for the development of ANB019 in GPP during the second half of 2020.
    • 02 Mar 2020 According to an AnaptysBio media release, the company has taken steps to enhance enrollment in this study, including expansion of clinical trial sites and countries.
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top